GILD · 10-Q · 2026Q3 · Full report

Oncology Product Expansion

GILEAD SCIENCES, INC. · 2026-10-30 · Importance 34 · Surprise 42

Trodelvy received European Commission authorization in combination with Keytruda for eligible first-line metastatic triple-negative breast cancer patients whose tumors express PD-L1. The FDA also approved Trodelvy for first-line locally advanced or metastatic triple-negative breast cancer, either as monotherapy for patients not eligible for PD-(L)1 inhibitor-based therapy or in combination with Keytruda or Keytruda Qlex for eligible PD-L1-expressing tumors. Separately, Tecartus received full FDA approval for adults with relapsed or refractory mantle cell lymphoma, including patients who are Bruton tyrosine kinase inhibitor-naïve.